

CURRICULUM VITAE

Name: **David P. Hajjar**

Place & Birth Date: Lawrence, Massachusetts
September 13, 1952

Home Address: 50 Sutton Place South, Apt. 6A
New York, N.Y. 10022
Tel: 646-649-4205

Office Address: Weill Cornell Medical College of Cornell University
1300 York Avenue
New York, New York 10065
Tel: 212-746-6900; Fax: 212-746-4527
Email address: dphajjar@med.cornell.edu

Education/Training: M.S. (1977) Biochemistry
Ph.D. (1978) Biochemistry
University of New Hampshire, Durham, N.H.

Post-Doctoral Fellow in Pathology
1978-1980, Preceptor: Dr. C. Richard Minick
Cornell University Medical College

Post-Doctoral Fellow in Biochemistry
1980-1981, Preceptor: Dr. Christian deDuve
Laboratory of Biochemical Cytology
The Rockefeller University

Professional Experience: Distinguished Professor of Pathology and Dean Emeritus of the Faculty
2013-present
Weill Cornell Graduate School of Medical Sciences
Cornell University
1300 York Avenue, New York, NY

Jefferson Science Fellow/Foreign Affairs Officer
2014-2015 (sabbatical leave)
U.S. State Department
Office of International Health and Disease
2201 C St, N.W. Suite 2734
Washington, D.C. 20520

Senior Fellow, Strategic Science Policy/Diplomacy Program

2013-2014

Belfer Center for Science and International Affairs
Harvard-Kennedy School of Government, Harvard University
79 JFK Street, Cambridge, Mass

Frank Rhodes Distinguished Professor of Cardiovascular Biology and Genetics

1997-2014

Weill Cornell Medical College, Cornell University
1300 York Avenue, New York, N.Y.

Dean of the Faculty

1997-2013

Weill Cornell Graduate School of Medical Sciences, Cornell University
1300 York Avenue, New York, NY

Senior Executive Vice Dean and Executive Vice Provost of Medical Affairs

2007-2012

Weill Cornell Medical College, Cornell University
1300 York Avenue, New York, NY

Vice Provost of the Faculty and Research Dean

2000-2007

Weill Cornell Medical College, Cornell University
1300 York Avenue, New York, NY

Director, Center of Vascular Biology

1995-2010

Weill Cornell Medical College, Cornell University
1300 York Avenue, New York, NY

Professor of Pathology and Biochemistry

1989-present

Cornell University Medical College
1300 York Avenue, New York, NY

Associate Professor of Pathology and Biochemistry

(tenured, 1986), 1984-1989

Cornell University Medical College
1300 York Avenue, New York, NY

Assistant Professor of Pathology and Biochemistry

1981-1984

Cornell University Medical College, 1300 York Avenue, New York, NY

Academic and Professional Honors:

Alpha Chi, National Honor Society, 1973
Phi Sigma Phi, Honorary Science Society, 1973
Phi Sigma, Biological Research Society, 1975
Who's Who in America, 1981
American Heart Association: Fellow, Council on Arteriosclerosis, 1982
Fellow, American Institute of Chemists, 1984
Tenured, Cornell University Medical College, 1986
Honorary Doctorate of Science (D.Sc), honoris causa, American International College, 1995
Sigma Xi Society National Lecturer, 1995
Chairman, Gordon Conference on Atherosclerosis, 1997
Honorary Fellow, Cornell University Medical College Alumni Association, 1997
Fellow of the AAAS, American Association of the Advancement of Science, 1997
Chairman, Keystone Conference on Inflammatory Paradigms and the Vasculature, 1999
Fellow, Royal Society of Medicine, 1999
Chairman, International Conference on Infection and Atherosclerosis,
Cardiovascular Research Foundation, 1999
Chairman, Keystone Conference on Inflammatory Paradigms and Vasculature II, 2002
President, American Association of University Pathologists, 2001-2002
Who's Who In Medical Education, 2005
Honorary Doctorate of Humane Letters (D.Litt), honoris causa, University of New Hampshire, 2014
Chairman, Gulf Research Meeting on Science and Technology, Education and Innovation in GCC Countries,
.....University of Cambridge, England, 2014
Foreign Policy Advisor, Brookings Institute, Washington, D.C., 2016-present

Awards:

National Merit Scholarship Award, 1969
American Chemical Society Award for Young Investigators, 1976
New Hampshire Heart Association Predoctoral Research Fellowship Award, 1976
U.S.P.H.S. Postdoctoral N.I.H. Research Fellowship Award, 1978
N.I.H. New Investigator Research Investigatorship Award, 1981
Andrew Mellon Foundation Teacher-Scientist Award, 1981, 1982
American Heart Association Established Investigator Award, 1984
American Society of Investigative Pathology (ASIP) Warner Lambert/Parke Davis Award, 1991
(for meritorious contributions in experimental pathology)
American Society of Investigative Pathology (ASIP) Chugai Award, 2003
(for excellence in mentoring and scholarship)
Fulbright Scholar Award, U.S. Department of State, 2010-2011
Jefferson Fellowship Award, National Academy of Sciences/ U.S. Department of State, 2014-2015
Weill Cornell Medical College Dedicated Service Award, 2014

Visiting Professorships in Vascular Biology/Pathology:

University of New Hampshire, Durham, NH, June, 1985
Wake Forest University, Winston-Salem, NC, June, 1986
University of Washington School of Medicine, Seattle, WA, Dec. 1988
Harvard University, Cambridge, MA, Nov. 1991
University of California, San Francisco, CA, Jan. 1993
Vanderbilt University Medical Ctr., Nashville, TN, May 1993
Washington University School of Medicine, St. Louis, MO, Nov. 1993
Harvard Medical School-Brigham and Women's Hospital, Boston, MA, Jan. 1997
University of California, Berkeley, CA, March 1998
University of California, Los Angeles, CA, Feb. 1999: Bojun Visiting Professorship
Tianjin Medical University, Tianjin, China, April 1999
Massachusetts Institute of Technology, Cambridge, MA, April 2006
Cornell University, NY State College of Veterinary Medicine, Ithaca, NY, March 2008
University of Naples, Naples, Italy, August 2009
University of Tokyo, Japan, November 2010
University of Rome, Italy, March 2011
University of Lugano, Switzerland, November 2011
University of New Hampshire, Durham, NH, April 2012

Scientific and Educational Society Affiliations:

American Chemical Society
American Society of Biochemistry and Molecular Biology
American Institute of Chemists
American Association of Advancement of Science
American Heart Association
American Association of University Professors
American Society of Investigative Pathology
New York Lipid Research Club
American Educational Research Association
New York Academy of Sciences
Harvey Society
Council of Graduate Schools, National Education Association
Council on Foreign Relations
Belfer Center on Science and International Affairs, Harvard-Kennedy School of Government

ACADEMIC RESPONSIBILITIESResearch Training:

<i>Ph.D. students</i>	<i>Training Period</i>	<i>Program and Present Position</i>
Charles Rosenberg	1980-1984	Cell Biology and Genetics, Professor, UCLA
Andrew C. Nicholson	1986-1991	Pathology, Assoc. Res. Professor., Weill Cornell Medical College
Cindy Levine	1990-1994	Pathology, Associate Professor, Columbia
Hongbin Men	1995-1999	Pathology, Associate Professor, UPenn, Philadelphia, PA
Li Sun	2000-2003	Pathology, Assistant Professor, Tianjin Med. University, China
George Moran	2012-2014	Pathology, Weill Cornell Medical College (left to go to Med.Sch)

<i>Post-doctoral Fellows</i>	<i>Training Period</i>	<i>Present Position</i>
Dr. Orli Etingin	1983-1986	Professor, Medicine, WCMC*
Dr. Alan Grant	1985-1986	Res Scientist II, Vascular Pathology Group, , CIBA-GEIGY, NJ
Dr. Kenneth Pomerantz	1985-1986	Director of Med. Publications, Boehringer Ingelheim, CT
Dr. Susan Morgello	1986-1987	Professor, Pathology, Mt. Sinai Med. College
Dr. Melvin Tiell	1987-1988	Professor, Pathology, SUNY-Buffalo, NY
Dr. Robert Kaner	1988-1991	Associate Professor, Medicine, WCMC
Dr. Rosemary Kraemer	1989-1992	Associate Res Professor, Pathology, WCMC, NY.NY
Dr. Alison Stopeck	1989-1993	Professor, Univ. of Arizona, Med School, Ariz. Cancer Ctr.
Dr. Andrew Nicholson	1991-1993	Associate Professor, Pathology, WCMC
Dr. Hsien-Yeh Hsu	1991-1994	Professor, Pathology, Taiwan National University
Dr. Frieda Pearce	1991-1994	Res Scientist II, Pathophysiology Div, Bristol-Myers Squibb, NJ
Dr. Roxanna Ursea	1992-1994	Assoc Professor, Opthal Pathology. ,University of Arizona
Dr. Harry Lander	1994-1995	Research Admin Manager, SIDRA Medical Center, Doha, Qatar
Dr. Rita Upmacis	1994-1997	Professor, Biochemistry, Pace University
Dr. Jihong Han	1996-1997	Professor and Chairman, Biochemistry, Nankai University, China
Dr. Jianwei Feng	1998-1999	Associate Professor, Pathology, Brooklyn Hospital, NY
Dr. Geeta Thakker	1999-2000	Associate Professor, Physiology, Univ. of Texas, Houston
Dr. Edward Tamer	1999-2000	Research Scientist II, Astra Zeneca, London, England
Dr. Ruba Deeb	1997-2002	Associate Research Professor, Pathology, WCMC
Dr. Dev Mittar	1999-2001	Associate Professor, Pathology, Nanak Dev Univ, Amritsar, India
Dr. Nikki Feirt	2000-2002	Associate Professor, Pathology Columbia University, NY, NY
Dr. Toru Yokoyama	2000-2002	Sen Res Scientist, Pathology Section, Kowa Corp, Tokyo, Japan
Dr. Michael Parsons	2001-2002	Associate Professor, Medicine, U. Mass, Worcester, MA
Dr. Hao Shen	2002-2005	Research Associate Professor, Pathology, WCMC
Dr. Wei He	2005-2006	Assistant Professor, Pathology, Duke University
Dr. Zhiping Huang	2006-2009	Assistant Member, Pathology, Hospital for Special Surgery, NY
Dr. Brian Lamon	2007-2010	Director, Cancer Liason Office, Bristol-Myers-Squibb, NJ

*WCMC = Weill Cornell Medical College, Cornell University

Faculty on Sabbatical Leave in My Laboratory

Dr. M. Tertov	1988-1989	Professor of Pathology, USSR Academy of Medicine, Moscow, Russia
Dr. J. Gertler	1989-1990	Professor of Surgery, Mass-General Hospital, Boston, MA
Dr. M. Naruszewicz	1999-2001	Professor of Pathology, Pomeranian Med Academy, Warsaw, Poland
Dr. R. Markle	2001-2002	Professor of Biology, Penn State University, PA
Dr. M. Stemerman	2003-2004	Professor and Divisional Dean, University of California, Riverside, CA

Teaching Activities at Weill Cornell Medical College and Graduate School, Cornell University

Medical College

Course: Medical Biochemistry for MD Students (1981-1996)

Course Directors: Esther Breslow and Owen Griffith

Lectures Taught by David P. Hajjar:

- Membrane Biochemistry I, II
- Prostaglandin Biochemistry
- Complex Lipids
- Cholesterol Metabolism
- Biochemistry of Cardiovascular Disease

Review Session: (weekly 3 hr. review session)

Course: MD/PhD Course in Biochemistry (1988-1993)

Course Directors and Lecturers: David P. Hajjar and Jeff Ravetch

Lectures Taught:

- Protein Turnover
- Diabetes
- Cardiovascular Disease
- Membranes – Signal Transduction
- Transcriptional Regulation w/Jeff Ravetch
- Clotting Cascades w/Rick Bucala
- Enzyme Kinetics
- Cachexia/Obesity w/Rick Bucala
- Techniques in Structural Biology w/John Kuriyana
- Regulation of Cell Growth w/Jeff Ravetch

Course: Molecules to Cells for MD and MD/PhD Students (1996-2001)

Course Director and Lecturer: David P. Hajjar

Lectures Taught:

- Membrane Biochemistry
- Prostaglandin Biochemistry
- Lipoproteins I, II

Conducted my own 10 week PBL session

Instructor of the Journal Club weekly session

Course: Concepts in Research Methodologies (2012- present)

Course Director and Lecturer: David P. Hajjar

7 Lectures taught by David P. Hajjar:

Fundamentals of Logic and Experimental Study Design
Responsible Conduct of Research (Ethics)
Responsible Conduct of Research (Human and Animal Research)
Art of the Presentation
Analysis of Scientific Papers I
Analysis of Scientific Papers II
Preparation of Research Grant Proposals

Course: Advanced Concepts in the Basic Sciences (2002-present)

2 Lectures taught by David P. Hajjar

Concepts of the Pathogenesis of Heart Disease I,II

Mini-Course to the Pathology Residents (2014-present)

Course Director and Lecturer: David P. Hajjar

3 Lectures taught by David P. Hajjar

Concepts of Research Methodology
Fundamentals of Clinical Epidemiology
Scientific Writing and the Art of Research Presentations

Graduate School

Course: Membrane Biochemistry (1985-1995)

Course Directors and Lecturers: David P. Hajjar and Marilyn Resh

6 Lectures Taught::

- Membrane Structure
- Methodologies to Study Membrane Structure
- Biosynthesis and Assembly
- Membrane Function
- Role of Membranes in Bioenergetic Metabolism
- Selected Topics in Signal Transduction

Course: Clinical Biochemistry for M.S. Program in Health Sciences (1981-present)

Course Director and Lecturer: David P. Hajjar

12 Lectures Taught::

Vitamins and Minerals

- Amino Acids and Proteins
- Enzyme Kinetics
- Acid Base Balance
- Carbohydrate Metabolism I, II
- Lipid Metabolism I, II
- Integration of Metabolism
- Extracellular Matrix and Cytoskeleton
- Digestive System
- Hormones

Intramural Committees at Weill Cornell Medical College:

1. Admissions Committees: (1982-1987)-M.D.; (1986-1990)-M.D./Ph.D.
2. Committee on Curriculum Review: (1986-1989)
3. Committee to Evaluate CUMC Ph.D. Qualifying Examinations: (1985)
4. General Faculty Council, Basic Science Member-at-Large: (1984-1987)
5. Chairman, Housing Committee: (1985-1987)
6. Task Force for Self-Study (LCME), Finance Committee: (1988)
7. Awards Committee: Cornell Univ. Graduate School: (1983-1987)
8. Institutional Review Committee for Awards: (1987-1989)
9. Committee of Review: Promotion and Tenure: (1988-1992)
10. Appeals Board for Professional Misconduct: (1988-1994)
11. M.D. with Honors in Research Committee: (1988-1995)
12. I.T. Hirschl Career-Scientist Award Selection Committee: (1988-1996)
13. PEW Scholars Selection Committee: (1991-1996)
14. Benefits Plan Administrative Committee: (1991-1994)
15. New York Hospital-Cornell Medical Ctr. Joint Board Strategic Planning Committee: (1992-1993)
16. Secretary, General Faculty Council: (1988-1990)
17. Vice-Chairman, General Faculty Council: (1990-1992)
18. Chairman, General Faculty Council: (1992-1994)
19. Chairman, Academic Computing Committee: (1991-1992)
20. CUMC Conflicts-of-Interest Committee: (1992-1997)
21. Chairman, Biochemistry Advisory Committee to develop new graduate program in Biochemistry and Structural Biology: (1993-1994)
22. Task Force for Industrial-Academic Relations: (1993-1995)
23. Committee to Review Graduate School at Cornell: (1994-1995)
24. Co-Chairman, CUMC Curriculum Planning Committee: (1994-1997)
25. Chairman, Basic Science Curriculum Subcommittee: (1994-1996)
26. Howard Hughes Institute Research Program Advisory Committee: (1995)
27. Chairman, Committee of Review, Graduate School: (1995-1997)
28. New York Hospital Board of Scientific Advisors: (1995-2000)
29. LCME Review Committees on Research, Education, and Governance and Administration: (1995-1996)
30. Research Planning Committee: (1995-2003)
31. Chairman, Research Services Subcommittee: (1995-1996)
32. Research Program Subcommittee: (1995-1996)
33. Financial Model Task Force Committee (1996-1997)
34. Chairman, Whitney Pavillion Facilities Committee (1997-1998)
35. Member, Board of Overseers for CUMC and their affiliated committees (1997 -2013)
36. Chairman, Subcommittee on Governance and Finance, Cornell Univ. Grad. School (1997-1998)
37. Member, MD/PhD Tri-Institutional Advisory Committee for Rockefeller University, Sloan-Kettering Institute and Cornell Medical School (1997-2013)
38. Member, Housing Committee (1997-2000)
39. Member, Dean's Advisory Committee (1997-2012)
40. Member, Post-Doctoral Task Force (1997-1999)

41. Chairman, Graduate School Executive Committee (1997-2012)
42. Member, Planning Coordinating Council for the Medical Center (1997-2002)
43. Member, New Capital and Program Initiatives Review Committee (1997-2002)
44. Member, Fringe Benefits Review Committee (2000-2002)
45. Member, Board of Directors, Griffis Faculty Club (2000-present)
46. Chairman, Search Committee to Select New Chairman of the Physiology and Biophysics Department of the Medical College (2000-2001)
47. Member, Search Committee to Select New Chairman of the Cell Biology Department for the Medical College (2000-2001)
48. Member, Search Committee to Select New Chairman of the Pediatrics Department for the Medical College (2000-2001)
49. Member, LCME Task Force on Research and Education, and Governance and Administration (Self-Study) for College Accreditation (2001-2002)
50. Member, Search Committee to Select New Chairman of Urology Department for the Medical College (2002-2003)
51. Member, Search Committee to Select New Chairman of Surgery Department for the Medical College (2002-2003)
52. Member, Search Committee to Select New Chairman of Otorhinolaryngology Department for the Medical College (2003-2005)
53. Member, Search Committee to Select New Chairman of the Department of Medicine for the Medical College (2004-2006)
54. Chairman, Strategic Plan III Committee - \$1.6 billion project to develop a new research building and new research, clinical, and educational programs for the Medical College, and to link the University's programs with the Medical College (2003-2006)
55. Member, Search Committee to Select New Chairman of the Department of Ophthalmology for the Medical College (2005-2006)
56. Chairman, Committee to Design New Research Programs for the Cornell Medical College Branch Campus in Doha, Qatar (\$180 million) (2004-2009)
57. Chairman, Task Force on Medical Education for the Medical College (2007)
58. Chairman, Task Force to Re-organize the Committee of Review and Promotions (2007)
59. Chairman, Strategic Plan Research Implementation Committee (2007-2010)
60. Chairman, Committee to Review the Academic Staff Policies and Procedures (2007-2008)
61. Chairman, Committee on Diversity and for the Establishment of an Office of Women in Science and Medicine (2008)
62. Vice Chairman, Search Committee for New Dean of Weill Cornell Medical College in Qatar (2008-2009)
63. Member, Steering Committee for the LCME Review for the Medical College (2008-2009)
64. Member, Search Committee to select a New Chairman of the Department of Neurology and Neurosciences for the Medical College (2011-2012)
65. Chairman, Research Development Task Force, for the Medical College (2010-2012)
66. Member, Medical Education Council, for the Medical College (2010-2014)
67. Chairman, Task Force to Implement the Medical College's Education Reforms Regarding its Curriculum (2011-2012)
68. Member, Planning Committee for the Center for Genomic Medicine, for the Medical College (2012)
69. Member, Planning Committee for the Cornell NYC-Technology campus (2012-2014)

70. Member, Starr Foundation Stem Cell Executive Committee (2006-2012)
71. Member, Starr Foundation Cancer Biology Executive Committee (2007-2012)
72. Member and Chair, Center for Health Informatics and Science Policy Advisory Committee (2012-2014)
73. Executive Committee for Scholarships for Medical Students (2015-present)

Extramural National Committees:

1. Council on Arteriosclerosis and Thrombosis, American Heart Association (1982-present)
2. Chairman, Program Committee, American Heart Association (1984-1986)
3. NIH Medical Biochemistry Study Section, Ad Hoc (1983-1987)
4. NIH Pathology A Study Section (1991-1995)
5. NIH National Heart, Lung, and Blood Institute, Program Project Committee (1998-2002)
6. NIH Specialized Centers of Research in Arteriosclerosis, Parent Committee (1986, 1991)
7. U.S. Veteran's Administration, Member, Biochemistry Merit Review Study Section (1985-1990)
8. Scientific Advisory Committee to the U.S. Congressional Biomedical Research Caucus, House of Representative's Appropriations Committee (1991-1992)
9. FASEB (ASIP), Public Affairs Committee (1991-1996)
10. Research Committee, American Heart Association (AHA), National Center (1992-1995)
11. FASEB (Amer Soc. Biochemists and Molecular Biologists) Program Committee (1991-1993)
12. FASEB Public Affairs Executive Committee (1993-1995)
13. Chairman, Vascular Biology Research Study Section, American Heart Association (1996-1999)
14. NIH/NASA Review Committee for NHLBI Grants (1993-1996)
15. Chairman, North American Vascular Biology Organization (AHA) Development Committee (2001-2003)
16. Reviewer, University of California Graduate School Programs (UCLA/UCR) (2003)
17. FASEB Committee on Shared Research Resources (2015-present)

Editorial Boards of Scientific Journals:

1. AHA Arteriosclerosis and Thrombosis (1990-1994)
2. AHA Circulation Research (1998-2001)
3. Journal of General Pharmacology (1999-2004)
4. Current Lipidology Reports (1998-2003)
5. Current Atherosclerosis Reports (1999-2009)
6. Journal of Lipid Research (1988-2000)
Associate Editor (1988-1993)
7. The Pathologist (2014-present), Cornell University, Co-Editor
8. Journal of Enzymology and Metabolism (2015-present)

Board Memberships (National and Intramural)

1. American Institutes of Chemists, Board of Scientific Affairs (1987-1990)
2. New York Hospital, NY, Board of Scientific Advisors (1995-2000)
3. NASA Board of Scientific Counselors (1998-2003)
4. Cornell University, Weill Cornell Medical College, Board of Overseers (1997-2012)
5. Cornell University Griffis Faculty Club, NY, NY. Board of Directors (1999-present)
6. New York Genome Center, NY, NY. Board of Directors (2011-2013)
7. Scientific Advisory Board, Therapeutic Solutions International, Inc. (2015-present)

**SUMMARY OF ADMINISTRATIVE ACCOMPLISHMENTS
(1980-1997)**

I. Program Development

Committee Chairman: Led initiative to design and implement a new Graduate Program in Biochemistry and Structural Biology. This program includes a faculty of 22 investigators from Cornell University Medical College and the Memorial-Sloan-Kettering Institute

II. Educational Development

Committee Chairman: Led initiative to revise the curriculum in the basic sciences for the medical and graduate students at Cornell University. Activities have also included working actively to develop and implement two "out-reach" programs to recruit under-privileged minority students for our federally-based research training programs in the Graduate School.

III. Research Training Development

Led initiative to develop NIH and Bristol-Myers-Squibb sponsored training grant programs at Cornell for pre- and post-doctoral graduate students. For 30 years, I served as Director of an NIH Training Grant (12 preceptors) for pre- and post-doctoral students in the area of vascular biochemistry. In 2003, I was awarded, as Principal Investigator, a Bristol-Myers 5-year grant to support graduate student training in experimental pathology.

Fund-Raising (Industrial Sector)

A successful effort was completed in 2005 to raise funds for graduate education in experimental pathology from the private and industrial sector. The following corporations and donors have provided these funds for the advancement of graduate education at the pre- and post-doctoral levels in the field of cell and vascular biology: Bristol-Myers-Squibb, Miles Laboratories, Symphar Corporation, Syntex Corporation, Astra Zeneca, and Kowa Corp.

IV. Research Center Development

In 1995, a Center of Vascular Biology was developed at Cornell University Medical College in which I served as the founding Director. 18 faculty from various basic and clinical science departments at Cornell participate in the educational and research mission of the Center. The Director's responsibilities include: the management of approximately \$3.0 million/year in federal and non-federal research funds, research space allocations within the Center (5000 sq.ft.), and personnel management between faculty, students, technicians, and staff of the Center with the medical center administration.

V. Research Services

Committee Chairman: Led initiative to design and implement new core and research services at Cornell University Medical College to better serve the research community at this institution.

SUMMARY OF ADMINISTRATIVE ACCOMPLISHMENTS (1997-2013)

Since my appointment as Dean in 1997, I implemented a \$20 million dollar new Strategic Plan for Research and Education within the Weill Cornell Graduate School of Medical Sciences. This included new curriculum changes, admission policies, social services, housing, program development, and endowment strategies. Our rankings in U.S. News and World Report improved, from #38 to #26.

Developed and implemented new academic international programs between Cornell University and Tianjin Medical University, Tianjin, China, in 1999 to foster the exchange of students and scholars between the two universities. In addition, I engineered an academic partnership between The Pasteur Institute, Paris, France and Weill Cornell Graduate School of Medical Sciences for the training of students beginning in 2005 based, in part, on our new strategic plan for the Graduate School. In 2008, an academic affiliation agreement was developed between Weill Cornell and Imperial College, London; and, in 2010, we did a similar affiliation agreement between Weill Cornell and the University of Tokyo.

As chief academic officer (Dean) of the Graduate School, I was responsible for budgeting, administrative, and alumni activities of our organization as well as implementation (annual budget ca \$10 million).

Designed new research and educational strategic plan (\$180 million) for the new medical college which I helped to develop at the Weill Cornell branch campus in Doha, Qatar in the Middle East. This initiative included the new research and training plan to foster collaborative interactions with the Medical College in New York City and our parent university in Ithaca, particularly with the Colleges of Arts and Sciences, Veterinary School, and Engineering. My responsibilities regarding our international programs in the Middle East, China, and France centered on operation and programmatic issues related to faculty affairs, research and training.

Participated in the Strategic Planning initiative to design and implement a new 430,000 gross sq. ft. research facility at The Methodist Hospital in Houston. This included the design of new academic programs in cancer, heart disease, global health, orthopedics, and diabetes.

Led a two-year strategic planning process to design and implement an overall \$1.7 billion dollar educational, research, and clinical plan for the Weill Cornell graduate school and medical college. Included in this initiative are plans to bring the Ithaca campus closer in line with the medical college campus in terms of its educational and research programs. In addition, we have built stronger bridges between our campus in Doha, Qatar with the medical college and graduate school in New York City.

Dealt with issues that arose between the administration and the faculty that relate to research and educational activities at our Medical Center. I also worked closely with our Chief Operating Officer in areas related to operations (facilities, housing, human resources, and budget / finance) to help serve the faculty at the medical center. I was also responsible for the research administrative budget for the College.

Designed and implemented joint MD/MBA and PhD/MBA programs with our Medical College, Graduate School of Medical Sciences, and the Johnson School of Management of Cornell University in Ithaca, N.Y.

Established a new Office of Faculty Diversity in Medicine and Science at Weill Cornell Medical College in 2009.

**SUMMARY OF MAJOR RESEARCH ACCOMPLISHMENTS
(1980-PRESENT)**

During the course of my scientific career, I

1. Identified the cytoplasmic cholesteryl esterase in the vessel wall as a distinct enzyme system which breaks down the storage form of cholesterol in the cell

Hajjar DP et al: Journal of Biological Chemistry 258:192-198, 1983.

2. Identified the regulatory elements which affect the esterase that controls cholesterol trafficking in the cell

Hajjar DP et al: Journal of Clinical Investigation 70:479-488, 1982.

Hajjar DP et al: Journal of Lipid Research 24:1176-1185, 1983.

Hajjar DP: Enzyme 32:218-227, 1984.

Hajjar DP: Biochemical Pharmacology 34:295-300, 1985.

Etingin OR and **DP Hajjar**: Journal of Clinical Investigation 75:1554-1558, 1985.

Etingin OR and **DP Hajjar**: Journal of Lipid Research 27:530-536, 1986.

Hajjar DP et al: Biochemistry 28:8885-8891, 1989.

Pomerantz KB and **DP Hajjar**: Biochemistry 29:1892-1899, 1990.

3. Discovered the role of herpesvirus infection in the regulation of cholesterol metabolism and thrombotic processes in cells and in an animal model of atherosclerosis

Fabricant CG, **Hajjar DP** et al: American Journal of Pathology 105:176-184, 1981.

Hajjar DP et al: Journal of Biological Chemistry 260:6124-6128, 1985.

Hajjar DP et al: American Journal of Pathology 122:62-70, 1986.

Hajjar DP: Journal of Biological Chemistry 261:7611-7614, 1986.

Hajjar DP et al: Journal of Clinical Investigation 80:1317-1321, 1987.

Hajjar DP et al: Proceedings of the National Academy of Sciences 86:3366-3370, 1989.

Etingin OR and **DP Hajjar**: Journal of Lipid Research 31: 299-305, 1990.

Etingin OR, RL Silverstein and **DP Hajjar**: Cell 61:657-662, 1990.

Baird A, RZ Florkiewicz, PA Maher, RJ Kaner and **DP Hajjar**: Nature 348:344-346, 1990.

Etingin OR et al: Proceedings of the National Academy of Sciences 88:7200-7203, 1991.

Altieri DC, OR Etingin, **DP Hajjar** et al: Science 254: 1200-1203, 1991.

Hajjar DP: American Journal of Pathology 139: 1195-1211, 1991.

Etingin OR et al: Proceedings of the National Academy of Sciences 90:5153- 5156, 1993

Hsu H et al: Journal of Biological Chemistry 270: 19630-19637, 1995.

4. Defined the role of nitrogen oxides in the control of eicosanoid and cholesterol metabolism

Hajjar DP et al: Journal of the American Chemical Society 117: 3340-3346, 1995.

Upmacis RK, RS Deeb and **DP Hajjar**: Biochemistry 38:12505-12513, 1999.

Upmacis RK et al: American Journal of Physiology, 286:C1271-1280, 2004.

Deeb RS et al: American Journal of Pathology, 168:349-362, 2006.

Deeb RS et al: Journal of the American Chemical Society, 132: 3914-3922, 2010.

Lamon BD et al: American Journal of Physiology, 229(3):H613-23, 2010.

5. Identified the adhesive protein, CD36, as a major scavenger receptor in oxidized lipoprotein trafficking

Han J, **DP Hajjar**, et al: Journal of Biological Chemistry 272:21654-21659, 1997.

Hsu HY, **DP Hajjar**, et al: Journal of Biological Chemistry 273:1240-1247, 1998.

Han J, **DP Hajjar**, et al: Journal of Lipid Research 40:830-838, 1999.

Febbraio M, **DP Hajjar**, et al: Journal of Biological Chemistry 274:19055-19062, 1999.

Feng JW, et al: Journal of Lipid Research 41:688-696, 2000.

Han J, **DP Hajjar**, et al: Journal of Biological Chemistry 275:241-1246, 2000.

Podrez EA, et al: Journal of Clinical Investigation 105:1095-1108, 2000.

Febbraio M, et al: Journal of Clinical Investigation 105:1049-1056, 2000.

Podrez EA, et al: Journal of Biological Chemistry 277:38517-38523, 2002.

INTERNATIONAL MEETINGS- INVITED LECTURES

1. 5th International Conference in Cyclic Nucleotides and Protein Phosphorylation (June 1983), University of Milan, Milan, Italy. "Prostacyclin Alters Cholesterol Metabolism by its Effect on Cyclic AMP in Arterial Smooth Muscle Cells."
2. Kyoto Conference on Prostaglandins (November 1984), Kyoto, Japan. "Prostacyclin and Cyclic Nucleotides Interact to Modulate Arterial Cholesterol Metabolism."
3. Tokyo Conference on Prostaglandins (December 1984), Tokyo Medical and Dental University, Tokyo, Japan. "Prostaglandins and Cholesterol Metabolism."
4. International Conference on Molecular Biology of Cardiovascular Disease (November 1987), Paris, France. "Molecular Aspects of Herpesvirus-Induced Arteriosclerosis."
5. 4th International Colloquium on Atherosclerosis (March 1988), Brussels, Belgium. "Role of Prostaglandins in Arteriosclerosis."
6. International Conference on Prostaglandins (March 1988), Paris, France. "Prostaglandin-Lipoprotein Interactions During Atherosclerosis."
7. Taipei Conference on Prostaglandin and Leukotriene Research (April 1988), Taipei, Taiwan, R.O.C. "Regulation of Cholesterol Metabolism by Eicosanoids and other Regulatory Signals."
8. 14th International Congress of Biochemistry (July 1988), Prague, Czechoslovakia. "Kinetics of Cholesteryl Ester Hydrolysis."
9. 8th International Symposium on Atherosclerosis (October 1988), Rome, Italy. "Cytokine network in arterial cell metabolism: cellular and molecular aspects."
10. International Symposium in Lipid Metabolism (February 1989), Heidelberg, Germany. "Prostaglandin-Cyclic AMP Activation of Cholesteryl Ester Hydrolase."
11. European Atherosclerosis Society (April 1989), Athens, Greece. "Cytokine Regulation of LDL Receptor Gene Transcription."
12. European Hypertension Society (June 1989), Milan, Italy. "Biochemical Basis of Atherosclerosis."
13. European Atherosclerosis Society (March 1990), Granada, Spain. "Molecular Mimicry in Atherogenesis."
14. International Symposium in Atherosclerosis (November 1990), Algarve, Portugal. "Molecular Mimicry During Atherogenesis."
15. International Meeting on Juvenile Diabetes (March 1992), Monaco, France. "Characterization of the Activation of Cholesteryl Ester Hydrolysis."

16. International Symposium on Lipid Metabolism (May 1992), Florence, Italy. "Signal Transduction Pathways Involved in Lipolysis."
17. International Academy of Pathology (June 1992), Toronto, Canada. "Molecular Mimicry During Atherosclerosis and Thrombosis."
18. Bayer International Conference in Atherosclerosis (February 1993), Regensburg, Germany. "Molecular Characterization of Coagulation Protease-Viral Glycoprotein Interactions."
19. European Vascular Biology Conference (March 1993), Courcheval, France. "Signal Transduction in Atherosclerosis."
20. Bayer Symposium-62nd European Atherosclerosis Society Congress (September 1993), Jerusalem, Israel. "Cytokine-LDL Receptor Activation of Cholesterol Metabolism."
21. 3rd Saratoga International Conference on Atherosclerosis (October 1993), Urabandai, Japan. "Molecular Modeling of the Coagulation Protease-Viral Glycoprotein Complexes."
22. United Nations International Conference on Atherosclerosis (June 1994), Miedzyzdroje, Poland. "Mechanisms of Atherosclerosis."
23. European Lipoprotein Society (September 1994), Munich, Germany. "Regulation of LDL-Cholesterol Trafficking by the Cytokine Network."
24. Institute of Scientific Research (November 1994), Paris, France. "LDL Receptor Activation by Inflammatory Mediators: Conformational Structural Changes and Altered Cholesterol Trafficking."
25. Wellcome Trust (September 1995), London, England. "Viral Activation of the Coagulation Cascade."
26. 3rd Scientific Meeting of the Polish Society for Atherosclerosis Research (October 1995), Cracow, Poland. "Role of the Cytokine Network in Arterial Cholesterol Trafficking."
27. 4th Saratoga International Conference on Atherosclerosis (Feb 1996), Honolulu, Hawaii. "Cytokine-LDL Receptor Activation of Cholesterol Metabolism."
28. 3rd Scandinavian Atherosclerosis Conference (May 1996), Copenhagen, Denmark. "CD36 is a Receptor for Oxidized LDL".
29. 68th European Atherosclerosis Society Conference (May 1997), Bruges, Belgium. "Macrophage Scavenger Receptors: Novel Binding Interactions with Oxidized Lipids"
30. 16th Congress of the International Society on Thrombosis (June 1997), Florence, Italy. "Macrophage Scavenger Receptors for Oxidized LDL".
31. 11th International Symposium on Atherosclerosis (October, 1997) Paris, France. "Macrophage Biology: New Avenues of Research Involving Cholesterol Trafficking".

32. International Society for Enzymology (May, 1998). Toronto, Canada. "Viral Pathogenesis of Atherosclerosis".
33. 13th International Symposium on Drugs Affecting Lipid Metabolism (May 1998). Florence, Italy. "Novel Lipoprotein Receptors in Vascular Cholesterol Trafficking".
34. International Symposium on Atherosclerosis (October 1998). Warsaw, Poland. "Novel Scavenger Receptors in Cholesterol Trafficking".
35. Conference on Infection and Atherosclerosis (December 1998). Annecy, France. "Viral Activation of the Coagulation Cascade".
36. 5th Saratoga Conference on Atherosclerosis (May 1999). Barcelona, Spain. "Cholesterol Trafficking in Macrophages by the CD36 Scavenger Receptor".
37. 5th International Symposium on Multiple Risk Factors in Cardiovascular Disease (October 1999). Venice, Italy. "Novel Scavenger Receptors in Cholesterol Trafficking".
38. 32nd Annual Meeting of the Japan Atherosclerosis Society (June 2000). Tokyo, Japan. "Role of CD36 in Atherosclerosis".
39. 11th International Vascular Biology Meeting (September 2000). Geneva, Switzerland. "Role of CD36 as a Macrophage Scavenger Receptor in Atherogenesis".
40. European Atherosclerosis Society Workshop on the Immune System (March 2001). Geneva, Switzerland. "Role of Macrophage Scavenger Receptors in the Pathogenesis of the Atherosclerotic Lesion".
41. International Conference on New Avenues in Atherosclerosis Research: Genomics and Therapeutical Perspectives (March 2001). Montreal, Canada. "Viral Activation of the Vessel Wall: Implications for Thrombo-Atherosclerosis".
42. 6th Saratoga International Conference on Atherosclerosis (April 2001). Tokyo, Japan. "CD36: A Macrophage Scavenger Receptor Involved in Atherogenesis".
43. 50th Annual American Association of University Pathologists Conference (February 2002). Turks and Caicos Islands, Great Britain. "Regulation of Cholesterol Trafficking in the Vessel Wall".
44. 6th International Symposium on Global Risk of Coronary Heart Diseases and Stroke (June 2002). Florence, Italy. "Regulation of PPAR-mediated Gene Expression: A New Mechanism of Action for HDL".
45. 2nd International Symposium on PPARs (March 2003). Florence, Italy. "Role of PPAR γ in the Regulation of Arterial Cholesterol Trafficking".
46. XIIIth International Symposium on Atherosclerosis (September 2003). Kyoto, Japan. "Role of Pitavastatin in Cholesterol Trafficking in the Vessel Wall".

47. XV International Symposium on Drugs Affecting Lipid Metabolism (October 2004). Venice, Italy. "Regulation of CD36 by PPAR During Atherogenesis: Impact on Cholesterol Accretion".
48. 2nd International Symposium on Triglycerides HDL and Metabolic Diseases (July 2005). New York, NY. "Role of CD36 and Other Macrophage Scavengers in Cholesterol Trafficking in the Vessel Wall."
49. 14th International Vascular Biology Meeting (June 2006). Noordwijkerhout, the Netherlands. "Scavenger Receptor Activation in the Vessel Wall".
50. 14th International Symposium on Atherosclerosis (June 2006). Rome, Italy. "Pathogenesis of Atherosclerosis: New Insights to this Aging Process".
51. European Atherosclerosis Society, 76th Congress (June 2007). Helsinki, Finland. "PPAR γ Regulation of Cholesterol Trafficking In the Vessel Wall".
52. XVI International Symposium on Drugs Affecting Lipid Metabolism (October 2007). New York, NY. "Nuclear Receptors in the Control of Cholesterol Trafficking".
53. 5th International Nanomedicine and Drug Delivery Symposium (November 2007). Boston, Mass. "Development of New Platform Technologies to Measure Cholesterol-Lipoprotein Receptor Interactions".
54. University of Naples, Department of Surgery (June 2008). Naples, Italy. "Role of the Cytokine/Eicosanoid Network in the Control of Cholesterol Metabolism and Efflux".
55. 7th International Symposium on Multiple Risk Factors in Cardiovascular Diseases-Health Policies (October 2008). Venice, Italy. "Heme-Oxygenase and Cyclooxygenase Pathways in Inflammatory Responses".
56. XV International Symposium on Atherosclerosis (June 2009). Boston, Mass. "Nitric Oxide Derivatives, Prostanoids, and Vascular Biology"
57. 8th International Congress on Coronary Artery Disease (October 2010). Prague, Czech Republic. "Heme is Critical in the Regulation of Prostaglandin Metabolism during Atherosclerosis"
58. 79th European Atherosclerosis Congress (June 2012). Gothenburg, Sweden. "Inflammatory Mediators which Trigger Arterial Cholesterol Accumulation".
59. 18th World Congress on Heart Disease. International Academy of Cardiology (July 2014). Toronto, Canada. "Inflammation and Arterial Cholesterol Efflux Thru Micro RNAs embedded in SREBP₂ and ABAC1".

RESEARCH SUPPORT AT WEILL CORNELL MEDICAL COLLEGE

Current Research Grant Support:

KOWA Pharmaceutical Corporation, Tokyo, Japan

Title: Regulation of Cholesterol Trafficking in Atherogenesis by MicroRNAs

Principal Investigator: David P. Hajjar

Period of Support: 2000-2016

Direct Costs: \$100,000/yr; Total Costs: \$2.5 million

Julia and Seymour Gross Foundation

Principal Investigator: David P. Hajjar

Period of Support: 2000-2016

Direct Costs: \$25,000 /yr; Total Costs: \$1.1 million

Previous Research Grant Support at Cornell, since 1978:

NIH PHS Postdoctoral Research Award, HL-05851 (F32)

Title: Regulation of Lipid Accretion-Metabolism

Principal Investigator: David P. Hajjar

Period of Support: 1978-1981

Direct Costs: \$15,400/yr; Total Costs: \$50,000

NIH Research Investigatorship Award, R23 HL-28179

Title: Characterization of Cholesteryl Ester Hydrolase in Atherogenesis

Principal Investigator: David P. Hajjar

Period of Support: 1981-1984

Direct Costs: \$51,400/yr; Total Costs: \$261,800

NIH SCOR-Thrombosis, HL-18828

Title: Ultrastructural Biology Core

Principal Investigator: David P. Hajjar

Period of Support: 1984-1986

Direct Costs: \$58,100/yr; Total Costs: \$200,000

New York Heart Association Senior Investigatorship for Research

Title: Activation of the Catalytic Domain of Cholesteryl Ester Hydrolysis

Principal Investigator: David P. Hajjar

Period of Support: 1981-1984

Direct Costs: \$31,000/yr; Total Costs: \$130,000

Andrew W. Mellon Foundation Teacher-Scientist Award

Awarded to Dr. David P. Hajjar for research on herpesvirus-induced arteriosclerosis
and teaching at Cornell University Medical College

Period of Support: 1981-1983

Direct Costs: \$15,000/yr; Total Costs: \$48,000

NIH Biomedical Research Support Grant, # 8605-008

Title: Molecular Biology of Herpesvirus-Induced Atherogenesis

Principal Investigator: David P. Hajjar

Period of Support: 1986-1987

Total Costs: \$150,000

American Heart Association Grant-In-Aid, #84-860

Title: Metabolic Alterations in Herpesvirus-Infected Cells in Atherogenesis.

Principal Investigator: David P. Hajjar

Period of Support: 1984-1987

Direct Costs: \$33,000/yr; Total Costs: \$132,000

NIH PHS, 1 R01 HL-35564

Title: Molecular Interactions in Atherogenesis

Principal Investigator: David P. Hajjar

Period of Support: 1985-1988

Direct Costs: \$108,000/yr; Total Costs: \$550,000

American Heart Association Established Investigatorship

Title: Viral Lipid-Protein Interactions in Atherogenesis

Principal Investigator: David P. Hajjar

Period of Support: 1984-1989

Direct Costs: \$31,500/yr; Total Costs: \$118,500

American Heart Association Grant-in-Aid, #87-813

Title: Eicosanoids and Lipoprotein-Induced Cholesterol Efflux

Principal Investigator: David P. Hajjar

Period of Support: 1987-1990

Direct Costs: \$30,000/yr; Total Costs: \$112,500

American Health Foundation, Grant-in-Aid

Title: Eicosanoid Metabolism during Arteriosclerosis

Co-Principal Investigator: David P. Hajjar

Period of Support: 1987-1990

Direct Costs: \$25,000/yr; Total Direct Costs: \$95,000

American Heart Association (New York Affiliate), Grant-in-Aid

Title: Activation of the Catalytic Domain of Cholesteryl Ester Hydrolase

Principal Investigator: David P. Hajjar

Period of Support: 1988-1991

Direct Costs: \$45,000/yr; Total Costs: \$165,000

NIH PHS, 1 R01 HL-39701

Title: Eicosanoid Regulation of Arterial Cholesterol Metabolism

Principal Investigator: David P. Hajjar

Period of Support: 1988-1993

Direct Costs: \$203,000/yr; Total Costs: \$1.1 million

NIH PHS, 1 R01 HL-45343

Title: Biochemistry of Growth Factor Receptor Interactions in Atherogenesis

Principal Investigator: David P. Hajjar

Period of Support: 1990-1994

Direct Costs: \$165,000/yr; Total Costs: \$510,000

NIH Subcontract from Scripps Institute, La Jolla, CA
Title: Structural Analysis of Factor X/Xa Catalytic Domain
Principal Investigator: David P. Hajjar
Period of Support: 1990-1995
Direct Costs: \$50,000/yr; Total Costs: \$300,000

NIH Biomedical Research Support Grant, #05396-29
Division of Research Resources
Title: Molecular Aspects of Cholesterol Metabolism
Period of Support: 1990-1992
Total Costs: \$80,000

NIH SCOR-Thrombosis, P50 HL-18828
Title: Regulation of Cholesterol Trafficking, Project V
Principal Investigator: David P. Hajjar
Period of Support: 1981-1986; 1986-1991; 1991-1996;
Direct Costs: \$167,000/yr; Total Costs: \$4.3 million (for the 15 yrs)

NIH PHS 1 R01-HL-49666
Title: G-Proteins Activation and Cholesterol Metabolism
Principal Investigator: David P. Hajjar
Period of Support: 1993-1998; 1998-2004
Direct Costs: \$300,000/yr; Total Costs: \$5.8 million for the 10 yrs

NIH Conference Grant, R13 HL/DK 58477
Title: Gordon Conference in Atherosclerosis
Principal Investigator: David P. Hajjar
Period of Support: 1997
Total Direct Costs: \$16,000

NIH SCOR - Molecular Medicine and Atherosclerosis, P50 HL-56987
Director of SCOR - David P. Hajjar
Principal Leader: David P. Hajjar, Project I
Title: CD36: A Novel Scavenger Receptor in Macrophage Foam Cells
Period of Support: 1997-2002
Direct Costs: \$1.3 million/yr; Total Costs: \$11.7 million

NIH PHS, 2 S07 RR018205

Title: Human Subjects Research Enhancement Program: Atherosclerosis

Principal Investigator: David P. Hajjar

Period of Support: 2004-2005

Total Direct Costs: \$250,000

NIH National Center of Research Resources C06 RR-020532

Title: RR-03-011 Extramural Research Facilities Construction Project for Center of Vascular Biology

Principal Investigator: David P. Hajjar

Period of Support: 2004-2006

Total Direct Costs: \$2.0 million

NIH Program Project Grant, NHLBI, P01-HL-72942

Title: The Atherogenic Microenvironment

Director, David P. Hajjar

Project Leader: Project I and Core A

Period of Support: 2003-2008

Direct Costs: \$1.2 million/yr; Total Costs: \$10.8 million

NIH National Research Service Award Training Grant, T32 HL-07423

Title: Vascular Biochemistry and Atherosclerosis

Director: David P. Hajjar

Period of Support: 1981-2010 (30 yrs)

Direct Costs: \$322,800/yr; Total Costs: \$11.6 million

NIH R01/RCI, HL091101 (ARRA Award)

Title: Eicosanoid Regulation in Atherosclerosis: Involvement of Inducible NO Synthase

Principal Investigator: David P. Hajjar

Period of Support: 2009-2012

Direct Costs: \$255,000; Total Costs: \$1.3 million

NIH Program Project Grant, NHLBI, P01-HL-46403

Title: Vascular Cell Signaling Pathways in Atherogenesis

Director: David P. Hajjar

Project Leader: Project V and Cores A and B

Period of Support: 1991-1996; 1996-2001; 2001-2006; 2006-2011; 2011-2015

Direct costs: \$1.3 million/yr; Total Costs: \$42 million.

Since my initial recruitment to Weill Cornell Medical College in 1978, I have been awarded approximately \$70 million in federal and non-federal research support (this includes direct and indirect costs).

SCIENTIFIC PUBLICATIONS

Ph.D. Dissertation:

Hajjar DP: Bioenergetic Metabolism and its Relationship to Lipid Synthesis during Atherogenesis. University of New Hampshire, Durham, NH, 1978

Original Research Papers:

1. **Hajjar DP**, TN Wight and SC Smith: Lipid accumulation and ultrastructural change within the aortic wall during early spontaneous atherogenesis. *American Journal of Pathology* 100:683-706, 1980.
2. Falcone DJ, **DP Hajjar** and CR Minick: Enhancement of cholesterol and cholesteryl ester accumulation in re-endothelialized aorta. *American Journal of Pathology* 99:81-104, 1980.
3. **Hajjar DP** and SC Smith: Focal differences in arterial bioenergetic metabolism of atherosclerosis-susceptible and resistant pigeons. *Journal of Atherosclerosis Research* 36:209-222, 1980.
4. **Hajjar DP**, DJ Falcone, S Fowler and CR Minick: Endothelium modifies altered metabolism of the injured aortic wall. *American Journal of Pathology* 102:28-39, 1981.
5. Eldor A, DJ Falcone, **DP Hajjar**, CR Minick and BB Weksler: Recovery of PGI₂ production by de-endothelialized aorta. Critical role of neointimal smooth muscle cells. *Journal of Clinical Investigation* 67:735-741, 1981.
6. Fabricant CG, **DP Hajjar**, CR Minick and J Fabricant: Herpesvirus infection enhances cholesterol and cholesteryl ester accumulation in cultured arterial smooth muscle cells. *American Journal of Pathology* 105:176-184, 1981.
7. Eldor A, DJ Falcone, **DP Hajjar**, CR Minick and BB Weksler: Diet-induced hypercholesterolemia inhibits the recovery of prostacyclin production by rabbit aorta. *American Journal of Pathology* 107:186-190, 1982.
8. **Hajjar DP**, BB Weksler, DJ Falcone, JM Hefton, and CR Minick: Prostacyclin modulates cholesteryl ester metabolism by its effect on cyclic AMP in aortic smooth muscle cells. *Journal of Clinical Investigation* 70:479-488, 1982.
9. **Hajjar DP**, CR Minick and S Fowler: Arterial neutral cholesteryl esterase: A hormone-sensitive enzyme distinct from lysosomal cholesteryl esterase. *Journal of Biological Chemistry* 258:192-198, 1983.

10. **Hajjar DP**, and BB Weksler: Metabolic activity of cholesteryl esters in aortic smooth muscle cells is altered by prostaglandins I₂ and E₂. *Journal of Lipid Research* 24:1176-1185, 1983.
11. **Hajjar DP**: Prostaglandins modulate arterial cholesteryl ester metabolism. *Enzyme* 32:218-227, 1984.
12. Falcone DJ, **DP Hajjar** and CR Minick: Lipoprotein and albumin accumulation in re-endothelialized aortic wall. *American Journal of Pathology* 114:112-120, 1984.
13. **Hajjar DP**: Prostaglandins and cyclic nucleotides: modulators of arterial cholesterol metabolism. *Biochemical Pharmacology* 34:295-300, 1985.
14. Salisbury BGJ, **DP Hajjar** and CR Minick: Altered glycosaminoglycan metabolism in injured rabbit aorta. *Experimental and Molecular Pathology* 42:306-319, 1985.
15. **Hajjar DP**, DJ Falcone, CG Fabricant, and J Fabricant: Altered cholesteryl ester cycle is associated with lipid accumulation in herpesvirus infected arterial smooth muscle cells. *Journal of Biological Chemistry* 260:6124-6128, 1985.
16. Etingin OR and **DP Hajjar**: Nifedipine increases cholesteryl ester hydrolytic activity in lipid-laden rabbit arterial smooth muscle cells: a possible mechanism for its anti-atherogenic effect. *Journal of Clinical Investigation* 75:1554-1558, 1985.
17. **Hajjar DP**, DJ Falcone, JB Amberson and JM Hefton: Interaction of arterial cells: I. Arterial endothelial cells alter cholesterol metabolism and endocytosis in co-cultured arterial smooth muscle cells. *Journal of Lipid Research* 26:1212-1223, 1985.
18. Becker CG, **DP Hajjar** and JM Hefton: Tobacco constituents are mitogenic for arterial smooth muscle cells. *American Journal of Pathology* 120:1-5, 1985.
19. **Hajjar DP**, CG Fabricant, CR Minick and J Fabricant: Virus-induced atherosclerosis. Herpesvirus infection alters arterial cholesterol metabolism and accumulation. *American Journal of Pathology* 122:62-70, 1986.
20. **Hajjar DP**: Regulation of neutral cholesteryl esterase in arterial smooth muscle cells: Stimulation by agonists of adenylate cyclase and cyclic AMP-dependent protein kinase. *Archives of Biochemistry and Biophysics* 247:49-56, 1986.
21. Etingin OR and **DP Hajjar**: Hydrolytic metabolites of prostacyclin increase cholesteryl ester catabolism in arterial smooth muscle cells. *Journal of Lipid Research* 27:530-536, 1986.
22. **Hajjar DP**: Herpesvirus infection prevents the activation of cytoplasmic cholesteryl esterase in arterial smooth muscle cells. *Journal of Biological Chemistry* 261:7611-7614, 1986
23. Hariri RJ, **DP Hajjar**, DR Alonso, and ME Weksler: Aging and Arteriosclerosis. I. Development of myointimal hyperplasia following endothelial injury. *Journal of Experimental Medicine* 164:1171-1178, 1986.

24. **Hajjar DP**, AJ Marcus and KA Hajjar: Interaction of arterial cells II. Studies on the mechanisms involved in endothelial cell modulation of cholesterol metabolism in co-cultured smooth muscle cells. *Journal of Biological Chemistry* 262:6976-6981, 1987.
25. **Hajjar DP**, DB Boyd, PC Harpel and RL Nachman: Histidine-rich glycoprotein reverses the anti-proliferative effect of heparin in arterial smooth muscle cells. *Journal of Experimental Medicine* 165:908-913, 1987.
26. Hajjar KA, **DP Hajjar**, and RL Nachman: Tumor necrosis factor-mediated increase of platelet-derived growth factor (PDGF) gene expression in human endothelial cells. *Journal of Experimental Medicine* 166:235-245, 1987.
27. **Hajjar DP**, KB Pomerantz, DJ Falcone and AJ Grant: Human herpes simplex virus infection in human arterial cells: Implications in Arteriosclerosis. *Journal of Clinical Investigation* 80:1317-1321, 1987.
28. Coico LS, **DP Hajjar**, Hefton JM and KA Hajjar: Interaction of arterial cells. III. Stathmokinetic analyses of the effects of endothelial cells on smooth muscle cell proliferation. *Journal of Cell Physiology* 134:485-490, 1988.
29. Hariri RJ, **DP Hajjar**, ME Weksler, DR Alonso: Aging and Arteriosclerosis. II. Cell cycle kinetics of young and old rat arterial smooth muscle cells. *American Journal of Pathology* 131:132-136, 1988.
30. **Hajjar DP**, IC Farber, and SC Smith: Oxygen tension within the arterial wall: relationship to altered bioenergetic metabolism and lipid accumulation. *Archives of Biochemistry and Biophysics* 262:375-380, 1988.
31. Pomerantz KB and **DP Hajjar**: Eicosanoid metabolism in cholesterol-enriched arterial smooth muscle cells: Altered arachidonate release with concomitant decreases in cyclooxygenase and lipoxygenase products. *Journal of Lipid Research* 30:1219-1233, 1989.
32. **Hajjar DP**, GN Sando, AC Nicholson, KA Hajjar and B Summers: Decreased messenger RNA in herpesvirus-infected arterial smooth muscle cells: effects on cholesteryl ester hydrolase. *Proceedings of the National Academy of Sciences* 86:3366-3370, 1989.
33. Hariri RJ, **DP Hajjar**, JB Ghajar, and KB Pomerantz: Human glial cell production of lipoxygenase-generated eicosanoids: a potential role in the pathophysiology of vascular changes following brain injury. *Journal of Trauma* 29:1203-1210, 1989.
34. **Hajjar DP**, AJ Marcus, and OR Etingin: Platelet-Neutrophil-Smooth Muscle Interactions: Inflammatory mediators such as the lipoxygenase-derived mono- and di-hydroxy acids activate arterial cholesteryl esterase by the cyclic AMP-dependent protein kinase cascade. *Biochemistry* 28:8885-8891, 1989.
35. Kaner RJ, A Baird, A Mansukhani, C Basilico, BD Summers, RZ Florkiewicz and **DP Hajjar**: Fibroblast growth factor receptor is a portal of entry for herpesvirus. *Science* 248: 1410-1413, 1990.

36. Etingin OR and **DP Hajjar**: Calcium channel blockers enhance cholesteryl ester hydrolysis and decrease cholesterol accumulation in human arterial tissue. *Circulation Research* 66:185-190, 1990.
37. Etingin OR and **DP Hajjar**: Evidence for cytokine regulation of cholesterol metabolism in herpesvirus-infected arterial cells by the lipoxygenase pathway. *Journal of Lipid Research* 31: 299-305, 1990.
38. Pomerantz KB and **DP Hajjar**: High density lipoprotein-induced cholesterol efflux from arterial smooth muscle-derived foam cells: functional relationship of the cholesteryl ester cycle and eicosanoid biosynthesis. *Biochemistry* 29:1892-1899, 1990.
39. **Hajjar DP**, KP Pomerantz and JW Snow: Structural analysis of the physical state of cholesteryl esters in smooth muscle derived-foam cells following herpesvirus-infection by differential scanning calorimetry. *Biochemical Journal* 268:693-697, 1990.
40. Etingin OR, RL Silverstein and **DP Hajjar**: Viral activation of the coagulation cascade: molecular interactions at the surface of infected endothelial cells. *Cell* 61:657-662, 1990.
41. Baird A, RZ Florkiewicz, PA Maher, RJ Kaner and **DP Hajjar**: Mediation of virion penetration into vascular cells by association of fibroblast growth factor. *Nature* 348:344-346, 1990.
42. Etingin OR, **DP Hajjar**, KA Hajjar and RL Nachman: Lipoprotein (a) modulates plasminogen activator inhibitor gene expression in endothelial cells: a potential mechanism in thrombogenesis. *Journal of Biological Chemistry* 266:2459-2465, 1991.
43. Kim JA, **DP Hajjar** and JA Berliner: B-VLDL induced alteration of endothelial cell plasma membranes: biochemical effects and immunocytochemistry. *Journal of Lipid Research* 32:1125-1142, 1991.
44. Etingin OR, RL Silverstein and **DP Hajjar**: Identification of a monocyte receptor on herpesvirus- infected endothelium. *Proceedings of the National Academy of Sciences* 88:7200-7203, 1991.
45. Altieri DC, OR Etingin, **DP Hajjar** and TS Edgington: Structurally homologous ligand binding of integrin Mac-1 and viral glycoprotein C receptors. *Science* 254: 1200-1203, 1991.
46. **Hajjar DP**: Viral pathogenesis of atherosclerosis: impact of molecular mimicry and viral genes. *American Journal of Pathology* 139: 1195-1211, 1991.
47. **Hajjar DP** and KB Pomerantz: Molecular motions and thermotropic phase behavior of cholesteryl esters: a deuterium nuclear magnetic resonance (NMR) spectroscopy study. *Biophysical Chemistry* 43:255-263, 1992.
48. Nicholson AC, KB Pomerantz, OR Etingin, and **DP Hajjar**: Dihydropyridine calcium antagonists modulate cholesterol and eicosanoid synthesis. *Journal of Cellular Biochemistry* 49: 393-400, 1992.
49. Nicholson AC and **DP Hajjar**: TGF- β 1 upregulates LDL receptor mediated cholesterol metabolism in vascular smooth muscle cells. *Journal of Biological Chemistry* 267:25982-25987, 1992.

50. Kraemer R., KB Pomerantz and **DP Hajjar**: Induction of basic FGF messenger RNA and protein synthesis in smooth muscle cells by cholesteryl ester enrichment and 25-hydroxycholesterol. *Journal of Biological Chemistry* 268:8040-8045, 1993.
51. Pomerantz KB, **DP Hajjar**, R Levi and SS Gross: Cholesterol enrichment of arterial cells upregulates cytokine-induced nitric oxide synthesis. *Biochemical Biophysical Research Communications* 191:103-109, 1993.
52. Etingin OR, RL Silverstein, and **DP Hajjar**: von Willebrand Factor mediates platelet adhesion to virally-infected endothelial cells. *Proceedings of the National Academy of Sciences* 90:5153- 5156, 1993.
53. Kaner RJ, J Medina, AC Nicholson, R Ursea, SM Schwartz and **DP Hajjar**: Age-related differences in herpesvirus plaque formation in vascular cells. *Circulation Research* 73: 10-14, 1993.
54. Stopeck A, AC Nicholson, F. Mancini, and **DP Hajjar**: Transcriptional regulation of the low density lipoprotein receptor by cytokines. *Journal of Biological Chemistry* 268: 17489-17494, 1993.
55. Pomerantz KP and **DP Hajjar**: Eicosanoid metabolism in cholesterol-enriched arterial smooth muscle cells. Evidence for reduced post-transcriptional processing of cyclooxygenase I and reduced cyclooxygenase II gene expression. *Biochemistry* 32:13624-13635, 1993.
56. Lang SJ, M Giordano, L Staiano-Coico, and **DP Hajjar**: Biochemical and cellular characterization of cardiac valve tissue following cryo-preservation or antibiotic preservation. *Journal of Thoracic and Cardiovascular Surgery* 108: 63-67, 1994.
57. Hsu HY, AC Nicholson, and **DP Hajjar**: Basic FGF-Induced LDL receptor transcription and surface expression: signal transduction pathways mediated by FGF receptor tyrosine and protein kinases. *Journal of Biological Chemistry* 269:9213-9220, 1994.
58. **Hajjar DP**, HM Lander, SFA Pearce, RK Upmacis, and KB Pomerantz: Nitric oxide enhances prostaglandin-H synthase-1 activity by a heme-independent mechanism: evidence implicating nitrosothiols. *Journal of the American Chemical Society* 117: 3340-3346, 1995.
59. Hsu HY, RJ Kaner, AC Nicholson, KP Pomerantz and **DP Hajjar**: Altered cholesterol trafficking in herpesvirus-infected arterial cells: evidence for viral protein kinase-mediated cholesterol accumulation. *Journal of Biological Chemistry* 270: 19630-19637, 1995
60. Donovan MJ, RC Miranda, R Kraemer, TA McCaffrey, **DP Hajjar** and BL Hempstead: Neurotrophin and neurotrophin receptors in vascular smooth muscle cells: regulation of expression in response to arterial injury. *American Journal of Pathology* 147:309-324, 1995.
61. Nicholson AC, KB Pomerantz, T. Fujimori, and **DP Hajjar**: Inhibition of cholesterol esterification in macrophages and smooth muscle foam cells: evaluation of ACAT inhibition. *Lipids* 30:771-774, 1995.
62. Kraemer R, T Scallen and **DP Hajjar**: Regulation of sterol carrier protein-2 (SCP-2) in cholesteryl ester-enriched arterial smooth muscle cells. *Journal of Lipid Research* 36:2630-2638, 1995.

63. Hsu HY, AC Nicholson and **DP Hajjar**: Inhibition of macrophage scavenger receptor activity by tumor necrosis factor (TNF) is transcriptionally and post-transcriptionally regulated. *Journal of Biological Chemistry* 271:7767-7773, 1996.
64. Nicholson AC, RL Nachman, D Altieri, BD Summers, TS Edgington, and **DP Hajjar**. Effector cell protease receptor is a vascular receptor for coagulation factor Xa. *Journal of Biological Chemistry* 271:28407-28413, 1996.
65. Lander HM, AJ Millbank, JM Tauras, **DP Hajjar**: A molecular redox switch on p21ras: structural basis for the nitric oxide - p21ras interaction. *Nature* 381: 380-381, 1996.
66. Madden MR, AA LaBruna, **DP Hajjar**, and L Staiano-Coico: Transplantation of cryopreserved cultured epidermal allografts. *Journal of Trauma* 40: 743-750, 1996.
67. Lander HM, **DP Hajjar**, B Hempstead, UA Mirza, BT Chait, S. Campbell-Burk, and LA Quilliam: Molecular redox switch in p21 ras: structural basis for the nitric oxide - p21 ras interaction. *Journal of Biological Chemistry* 272: 4323-4326, 1997.
68. Pomerantz KB, BD Summers, HM Lander, **DP Hajjar**: G-Protein-Mediated Signaling in Cholesterol-Enriched Arterial Smooth Muscle Cells: I. Reduced membrane-associated G -protein content due to diminished isoprenylation of G γ -subunits and p21 ras. *Biochemistry* 36: 9523-9531, 1997.
69. Pomerantz KB, BD Summers, **DP Hajjar**: G-Protein Mediated Signaling in Cholesterol-Enriched Arterial Smooth Muscle Cells: II. G-Protein-dependent eicosanoid regulation by protein kinase C- δ . *Biochemistry* 36: 9532-9539, 1997.
70. Upmacis R, BT Chait, UA Mirza, and **DP Hajjar**: First observation of nitrosylated heme in myoglobin and hemoglobin by electrospray ionization-mass spectrometry. *Journal of the American Chemical Society* 119 (43): 10424-10429, 1997.
71. Han J, **DP Hajjar**, and AC Nicholson: Native and modified low density lipoproteins increase the functional expression of the macrophage class B scavenger receptor, CD36. *Journal of Biological Chemistry* 272:21654-21659, 1997.
72. Hsu HY, **DP Hajjar**, and DJ Falcone: Ligand binding to macrophage scavenger receptor induces urokinase-type plasminogen activator expression through a protein kinase-dependent signaling pathway. *Journal of Biological Chemistry* 273:1240-1247, 1998.
73. Pearce SFA, M Febbraio, AC Nicholson, **DP Hajjar** and RL Silverstein: Recombinant GST/CD36 fusion proteins define an oxidized LDL binding domain. *Journal of Biological Chemistry* 273:34875-34881, 1998.
74. Thakker GD, **DP Hajjar**, WA Muller and T Rosengart: Role of the phosphoinositide 3-kinase pathway in vascular endothelial growth factor signaling. *Journal of Biological Chemistry* 274:10002-10007, 1999.

75. Han J, **DP Hajjar**, and AC Nicholson: Cellular cholesterol regulates expression of the macrophage type B Scavenger receptor, CD36. *Journal of Lipid Research* 40:830-838, 1999.
76. Febbraio M, **DP Hajjar**, K Sharma, SFA Pearce, and RL Silverstein: Functional role of the novel scavenger receptor, CD36, in lipoprotein transport: new insights from a CD36 null mouse. *Journal of Biological Chemistry* 274:19055-19062, 1999.
77. Upmacis RK, RS Deeb and **DP Hajjar**: Regulation of prostaglandin H2 synthase activity by nitrogen oxides. *Biochemistry* 38:12505-12513, 1999.
78. Feng JW, J Han, SF Pearce, RL Silverstein, AM Gotto, **DP Hajjar** and AC Nicholson: Induction of CD36 expression by oxidized LDL, M-CSF, and IL-4 by a common signaling pathway dependent on protein kinase C and PPAR γ . *Journal of Lipid Research* 41:688-696, 2000.
79. Han J, **DP Hajjar**, JM Tauras, AM Gotto, and AC Nicholson: Transforming growth factor- β 1 and TGF β 2 decrease expression of CD36, the type B scavenger receptor, through MAP kinase phosphorylation of PPAR γ . *Journal of Biological Chemistry* 275:241-1246, 2000.
80. Podrez EA, M Febbraio, RL Silverstein, **DP Hajjar**, PA Cohen, WA Frazier, HF Hoff and SL Hazen: Macrophage scavenger receptor, CD36, is the major receptor for LDL modified by monocyte-generated reactive nitrogen species. *Journal of Clinical Investigation* 105:1095-1108, 2000.
81. Febbraio M, EA Podrez, JD Smith, SL Hazen, **DP Hajjar** and RL Silverstein: Targeted disruption of the class B scavenger receptor, CD36, protects against atherosclerotic lesion development in mice. *Journal of Clinical Investigation* 105:1049-1056, 2000.
82. Deora A, **DP Hajjar**, and HA Lander: Recruitment and activation of Raf-1 kinase by nitric oxide-activated ras. *Biochemistry* 39:9901-9908, 2000.
83. Han, J, AC Nicholson, X Zhou, AM Gotto, Jr., and **DP Hajjar**: Oxidized LDL decreases macrophage expression of scavenger receptor B-I (SR-BI). *Journal of Biological Chemistry* 276:16567-16572, 2001.
84. Deeb RS, D Mittar, TA McCaffrey, **DP Hajjar**, and RK Upmacis: Tyrosine nitration of prostaglandin H2 synthase. *Journal of Lipid Research* 43:1718-1726, 2002.
85. Podrez EA, E Poliakov, Z Shen, M. Febbraio, **DP Hajjar**, RL Silverstein, H Hoff and SL Hazen: A novel family of atherogenic oxidized phospholipids promotes macrophage foam cell formation via the scavenger receptor, CD36 and is enriched in atherosclerotic lesions. *Journal of Biological Chemistry* 277:38517-38523, 2002.
86. Han J, **DP Hajjar**, X Zhou, AM Gotto, and AC Nicholson: Regulation of PPAR γ -mediated gene expression: a new mechanism of HDL action. *Journal of Biological Chemistry* 277:23582-23586, 2002.
87. Sun L, AC Nicholson, **DP Hajjar**, AM Gotto, and J Han: Adipogenic differentiation agents regulate expression of fatty acid binding protein (ap2) and CD36 in macrophages. *Journal of Lipid Research* 44:1877-1886, 2003.

88. Markle RA, J Han, T Yokoyama, KA Hajjar, **DP Hajjar**, AM Gotto and AC Nicholson: Pitavastatin alters the expression of thrombotic and fibrinolytic proteins in human vascular cells. *Journal of Cellular Biochemistry* 90:23-32, 2003.
89. Han J, X Zhou, **DP Hajjar**, AM Gotto and AC Nicholson: Pitavastatin down regulates expression of the macrophage type B scavenger receptor, CD36. *Circulation* 109(6):790-796, 2004.
90. Upmacis RK, MJ Resnick, D Mittar, RS Deeb and **DP Hajjar**: Involvement of the mitogen-activated protein kinase cascade in peroxynitrite-mediated arachidonic acid release in vascular smooth muscle cells. *American Journal of Physiology* 286:C1271-1280, 2004.
91. Han J, M Parsons, X. Zhou, AC Nicholson, AM Gotto and **DP Hajjar**: Functional interplay between macrophage scavenger receptor class B, type I (SR-B1) and pitavastatin. *Circulation* 110:3472-3479, 2004.
92. Deeb, RS, H Shen, C Gamss, T Gavrilova, S S Gross, N Maeda, **DP Hajjar**, RK Upmacis: Inducible nitric oxide synthase mediates prostaglandin H2 synthase nitration and suppresses eicosanoid production. *American Journal of Pathology* 168:349-362, 2006.
93. Deeb, RS, G Hao, SS Gross, M Laine, B Resnick, EJ Barbar, **DP Hajjar** and RK Upmacis: Heme catalyzes tyrosine 385 nitration and inactivation of prostaglandin H2 synthase-1 by peroxynitrite. *Journal of Lipid Research* 47:898-911, 2006.
94. **Hajjar DP**, AC Nicholson, X Zhou, W He, AM Gotto, Jr., and J Han: Anti-adipogenic action of pitavastatin occurs through the coordinate regulation of PPAR γ and Pref-1 expression. *British Journal of Pharmacology* 151:807-815, 2007.
95. Upmacis RK, M Crabtree, R Deeb, H Shen, P Lane, N Maeda, **DP Hajjar**, and SS Gross: Profound biopterin oxidation and protein tyrosine nitration in tissues of apoE-null mice on an atherogenic diet: contribution of inducible nitric oxide synthase. *American Journal of Physiology* 293:H2878-H2887, 2007.
96. Han J, X Zhou, W He, Z Huang, AM Gotto, Jr., and **DP Hajjar**: Genetic deletion of LDL receptor impairs sterol-induced mouse macrophage ABCA1 expression: a new SREBP-1 dependent mechanism. *Journal of Biological Chemistry* 283:2129-2138, 2008.
97. Huang Z, AC Nicholson, AM Gotto, Jr., J. Han, and **DP Hajjar**: Activation of PPAR γ in mice induces hepatic LDL receptor expression. *British Journal of Pharmacology* 155: 596-605, 2008.
98. Lamouche BD, BD Summers, AM Gotto, Jr., and **DP Hajjar**: Pitavastatin suppresses mitogen activated protein kinase-mediated Erg-1 induction in human vascular smooth muscle cells. *European Journal of Pharmacology* 606:72-76, 2009
99. Nakaya H, BD Summers, AC Nicholson, AM Gotto, Jr., **DP Hajjar**, J Han: Atherosclerosis in LDL-R knockout mice is inhibited but not reversed by the PPAR γ ligand pioglitazone. *American Journal of Pathology* 174:2007-2014, 2009.

100. Zhou X, Z Yin, X Guo, J Han and **DP Hajjar**: Inhibition of ERK 1/2 and activation of LXR synergistically induce macrophage ABCA1 expression and free cholesterol efflux. *Journal of Biological Chemistry* 285:6316-6326, 2010.
101. Deeb RS, C Cheung, T Nuriel, BD Lamon, R Upmacis, SS Gross, and **DP Hajjar**: Physical evidence for substrate binding in preventing cyclooxygenase inactivation under nitrate stress. *Journal of the American Chemical Society* 132: 3914-3922, 2010.
102. Lamon, BD, RK Upmacis, RS Deeb, H Koyuncu, and **DP Hajjar**: Inducible nitric oxide synthase gene deletion exaggerates MAPK- mediated cyclooxygenase –2 induction by inflammatory stimuli. *American Journal of Physiology* 229(3):H613-23, 2010.
103. Upmacis RK, H Shen, LES Benguigui, BD Lamon, RS Deeb, KA Hajjar, and **DP Hajjar**. Inducible nitric oxide synthase provides protection against injury-induced thrombosis. *American Journal of Physiology* 301(2): H617-624, 2011.
104. Duan Y, Y Chen, W Hu, X Li, X Zhou, D Kong, **DP Hajjar**, and J Han: PPAR γ activation by ligands and dephosphorylation induces PCSK9 and LDL receptor expression. *Journal of Biological Chemistry* 287(28):23667-23677, 2012.
105. Chen Y, Y Duan, Y Kong, Y Kang, M.Jiang, W Hu, P Dong, **DP Hajjar**, and J Han: Activation of liver X receptor induces macrophage interleukin-5 expression. *Journal of Biological Chemistry* 287: 43340-43350, 2012
106. Deeb RS, T Nuriel, C Cheng, B Summers, BD Lamon, SS Gross and **DP Hajjar**: Characterization of a cellular denitrase activity that reverses nitration of cyclooxygenase in the vessel wall. *American Journal of Physiology* 305: H687-698, 2013.
107. Jiang,M., L. Zhang, X. Ma,Y. Chen, X. Li, Y. Zhu, **DP Hajjar**, Y. Duan, and J. Han: Tamoxifen inhibits macrophage fatty acid binding protein (FABP4) expression by a glucocorticoid receptor and PPAR combinational pathway. *Biochemical Journal* 454: 467-477, 2013.
108. Wang Q., X. Ma, Y. Chen, L. Zhang, X. Li, R. Miao, Y. Duan, **DP Hajjar** and J. Han: Activation of liver X receptor induces interferon production and inhibits tumor growth. *Biochemical Journal* 459:345-354, 2014.
109. Chen, Y, Y. Duan, X. Yang, L. Sun, , R Maio, W. Zhang, R. Xiang, **DP Hajjar** and J. Han: Inhibition of ERK 1/2 and activation of LXR synergistically reduce atherosclerotic lesions in apoE deficient mice. *Arteriosclerosis, Thrombosis and Vascular Biology (ATVB)* 35: 948-959, 2015
110. Zhang H., BD Lamon, G Moran, T. Sun and **DP Hajjar** : Pitavastatin differentially modulates micro RNA-associated cholesterol transport proteins in macrophages. *Plos One*, accepted with revisions, 2016
111. Zhang L, Y.Chan, X. Yang, L.Yuan-Li, QR Miao, **DP Hajjar** and J. Han: MEK 1/2 inhibitors activate macrophage ABCG1 expression and reverse cholesterol transport : an anti-atherosclerosis function of ERK 1/2 inhibition. *Arteriosclerosis, Thrombosis and Vascular Biology (ATVB)*, submitted, 2016

Review Articles:

1. **Hajjar DP** and SC Smith: Mitochondrial ATPase activation: characterization of activity during spontaneous atherosclerosis. *Artery* 4:463-479, 1978.
2. Minick CR, DJ Falcone and **DP Hajjar**: Endothelium in Experimental Atherosclerosis. In: *Atherosclerosis V. Proceedings of the Vth International Symposium*. Ed. AM Gotto, Jr., et al. Springer-Verlag Press, New York, pp 563-566, 1980.
3. Minick CR, **DP Hajjar** and DJ Falcone: Role of injury in arterial wall metabolism. In: *Pathobiology of Endothelial Cells*. Eds. Academic Press, New York, pp 323-335, 1982.
4. Minick CR, **DP Hajjar**, DJ Falcone, CG Fabricant and J Fabricant: Endothelial injury and arterial lipid metabolism. In: *Proceedings of a Workshop in Diabetes and Atherosclerosis*. NIH Publication Series: 1983.
5. Weksler BB, **DP Hajjar**, DJ Falcone, and KT Goldman: Interactions between prostacyclin (PGI₂) metabolism and cholesteryl ester metabolism. In: *Advances in Prostaglandins, Leukotriene and Thromboxane Research*: Eds. B Samuelsson, et al. Vol 11, Raven Press, New York, pp 463-467, 1983.
6. Minick CR, **DP Hajjar** and DJ Falcone: Correlation of morphological and biochemical components of atherosclerotic plaques. In: *Clinical Diagnosis of Atherosclerosis*. Eds. MG Bond, et al. Springer-Verlag, New York, pp 369-388, 1983.
7. **Hajjar DP**: Prostacyclin and cyclic nucleotides interact to modulate arterial cholesteryl ester metabolism. In: *Advances in Cyclic Nucleotide and Protein Phosphorylation Research*. Eds. P Greengard et al, Raven Press, New York, Vol 17, pp 605-614, 1984.
8. **Hajjar DP**: Interaction of Prostacyclin and Arterial Cholesterol Metabolism. In: *Interaction of Platelets with the Vessel Wall*. American Physiological Society, Clinical Series, Eds. JA Oates, J. Hawiger and R. Ross. Ch. 11, pp 125-138, 1985.
9. **Hajjar DP**: Modulation of arterial cholesteryl ester metabolism by prostaglandins I₂ and E₂. In: *Advances in Prostaglandin, Thromboxane, and Leukotriene Research*. Eds. O. Hayaishi and S. Yamamoto. Raven Press, New York, Vol. 15, pp 249-252, 1985.
10. **Hajjar DP** and BGJ Salisbury: Endothelial-smooth muscle cell interactions during atherosclerosis. *Pathology and Immunopathology Research* 5: 437-454, 1986.
11. **Hajjar DP**, CG Fabricant, and J Fabricant: Herpesvirus-induced atherosclerosis. *Comparative Pathology* 18:2-6, 1986
12. **Hajjar DP**, CG Fabricant, and J Fabricant: Herpesvirus- induced atherosclerosis in chickens: a new animal model to study atherogenesis. *Handbook: Animal Models of Human Disease*, 16th edition. Registry of Comparative Pathology, Armed Forces Institute of Pathology, Washington, DC, 1987.

13. **Hajjar DP**, AJ Marcus, and KA Hajjar: Arterial endothelial cell-derived eicosanoids alter cholesterol metabolism in arterial smooth muscle cells. *Ann NY Academy of Science* 524:411-413, 1988.
14. Hariri RJ, J Ghagar, KB Pomerantz and **DP Hajjar**: Human glial production of lipoxygenase-generated eicosanoids. *Surgical Forum* 39: 483-489, 1988.
15. **Hajjar DP**: Arterial Cell Interactions: Mechanistic studies related to eicosanoid and growth factor-induced alterations in cholesterol. *Adv. Exp. Med. Biol: Lipoproteins and Atherosclerosis*. Ed. by C.L. Malmendier and P. Alaupovic, Vol. 243, Plenum Press, NY, NY, pp. 37-45, 1988.
16. **Hajjar DP** and KB Pomerantz: Eicosanoids and their role in atherosclerosis. *Arch. Mal. Coeur* 82:21-26, 1989.
17. Pomerantz KB and **DP Hajjar**: Eicosanoids in the regulation of arterial smooth muscle cell phenotype, proliferative capacity and cholesterol metabolism. *Arteriosclerosis* 9:413-429, 1989.
18. **Hajjar DP** and KB Pomerantz: Cicletanine interactions with cholesteryl ester and PGI₂ synthesis in arterial cells. *Arch. Mal. Coeur* 82:79-84, 1989.
19. Pomerantz KB and **DP Hajjar**: Prostanoids as signal transducers in lipid metabolism. *Current Opinions in Lipidology* 1:422-430, 1990.
20. Shepard SR, RJ Hariri, K Pomerantz, **DP Hajjar** and JBG Ghajar: Leukotiene production by human glia. *Acta Neurologica Suppl.* 51:58-60, 1990.
21. **Hajjar DP** and KB Pomerantz: Role of eicosanoids and the cytokine network in transmembrane signaling in vascular cells In: *Cell-Cell Interactions in the Release of Inflammatory Mediators*. Plenum Press, New York, pp. 159-183, 1991.
22. **Hajjar DP** and AC Nicholson: Signal transduction in the arterial wall: Role of eicosanoids and the cytokine network in the regulation of lipolysis In: *Atherosclerosis Reviews*, Vol 23, Raven Press, New York, edited by PC Weber and A Leaf, pp.31-40, 1991.
23. Kaner RJ and **DP Hajjar**: Viral Genes and Atherogenesis In: *Genetic Factors in Atherosclerosis-Candidate Genes and Processes*, edited by AJ Lusis, JL Rotter and RS Sparks., *Monographs in Human Genetics*, Karger, New York, Vol 14, pp. 62-81, 1992.
24. **Hajjar DP** and KB Pomerantz: Signal transduction: integration of eicosanoids and the cytokine network. *FASEB J* 6:2933-2941, 1992.
25. Etingin OR, and **DP Hajjar**: Viral activation of the coagulation protein cascade. *Seminars in Virology* 3:125-133, 1992.
26. Marcus AJ and **DP Hajjar**: Vascular transcellular signaling: *Journal of Lipid Research* 34: 2017- 2032, 1993.

27. Pomerantz KB, AC Nicholson, OR Etingin and **DP Hajjar**: Biochemical mechanisms associated with the lipolytic effects of calcium channel blockers. In: Proceedings XI International Symposium on Drugs Affecting Lipid Metabolism. ED AM Gotto and R Paoletti, Klurver Academic Publishers, Netherlands, 1993.
28. **Hajjar DP**: Regulation of Cholesteryl Ester Hydrolases. In: Advances in Enzymology, Ed. by A. Meister, Vol.69, Chapt 2, pp. 45-82, 1994.
29. Pomerantz KP, AC Nicholson and **DP Hajjar**: Signal transduction in atherosclerosis: second messengers and regulation of cellular cholesterol trafficking. In: Nutrition and Biotechnology in Heart Disease and Cancer. D Kritchevsky, M. Drezner and J. Longenecker, eds., Plenum Publishing Co., New York, pp. 49-64, 1995.
30. Nicholson AC and **DP Hajjar**: Viral induction of endothelial cell procoagulant activity. In: Vascular Control of Hemostasis. VWM van Hinsbergh, ed. Gordon and Breach Publishers, the Netherlands, Ch. 16, pp. 299-308, 1995.
31. Nicholson AC, **DP Hajjar** and RL Silverstein: Effect of anti-CD36 antibodies on the binding of oxidized LDL to CD36-transfected cells. In: Leukocyte Typing V: White Cell Differentiation Antigens. SF Schlossman and RF Todd, eds., Oxford University Press, pp. 1278-1280, 1995.
32. **Hajjar DP** and AC Nicholson: Atherosclerosis. American Scientist 83:460-467, 1995.
33. Kaner RJ and **DP Hajjar**: Viral activation of thrombo-atherosclerosis. In: Atherosclerosis and Coronary Artery Disease. R. Ross, V. Fuster, and E. Topol, eds., Lippincott-Raven Press, Philadelphia, Ch. 32, pp.569-584, 1996.
34. Nicholson AC, RJ Kaner, **DP Hajjar**: Role of herpesviruses in atherosclerosis and thrombosis. In: Coronary Restenosis: From genetics to therapeutics. GZ Feuerstein, ed. Marcel Dekker, Inc., New York. Ch. 10. pp. 177-205, 1997.
35. **Hajjar DP** and AC Nicholson: Viral activation of coagulation: implications for thrombosis and atherosclerosis. Ann NY Acad Sci 811:155-167, 1997.
36. **Hajjar DP** and ME Haberland: Lipoprotein trafficking in vascular cells: molecular trojan horses and cellular saboteurs. Mini-Review. Journal of Biological Chemistry 272:22975-22978, 1997.
37. Nicholson AC and **DP Hajjar**: Herpesviruses in atherosclerosis and thrombosis: etiological agents or ubiquitous bystanders. Arteriosclerosis and Thrombosis 18:339-348, 1998.
38. Nicholson AC and **DP Hajjar**: Herpesviruses and thrombosis: activation of coagulation on the endothelium. Clinica Chimica Acta 286:23-29, 1999.
39. **Hajjar DP**: Oxidized Lipoproteins and Infectious Agents: Are they in Collusion to Accelerate Atherogenesis? Arteriosclerosis and Thrombosis 20:1417-1420, 2000.

40. Epstein SE, J Zhu, MS Burnett, G Vercellotti and **DP Hajjar**: Infection and Atherosclerosis: Potential Roles of Pathogen Burden and Molecular Mimicry. *Arteriosclerosis and Thrombosis* 20:1421-1422, 2000.
41. Nicholson AC, M Febbraio, J Han, RL Silverstein, **DP Hajjar**: CD36 in atherosclerosis: role of a class B macrophage scavenger receptor. *Ann NY Acad Sci* 902:128-133, 2000.
42. Nicholson AC, J Han, M. Febbraio, SFA Pearce, AM Gotto and **DP Hajjar**: CD36, the macrophage class B scavenger receptor: regulation and role in atherosclerosis. In: *Atherosclerosis and Autoimmunity*. Y. Shoenfeld, D. Harats and G. Wick, eds. Elsevier, Amsterdam. pp. 41-47, 2001.
43. Nicholson AC, J Han, M Febbraio, RL Silverstein and **DP Hajjar**: Role of CD36, the macrophage class B scavenger receptor, in atherosclerosis. *Ann NY Acad Sci* 947:224-228, 2001.
44. Upmacis RK, R Deeb and **DP Hajjar**: Role of nitrogen oxides on eicosanoid production during atherosclerosis: understanding the controversies. *Current Atherosclerosis Reports* 3(3):181-182, 2001.
45. Febbraio M, **DP Hajjar** and RL Silverstein: CD36: A class B scavenger receptor involved in angiogenesis, atherosclerosis, inflammation, and lipid metabolism. *Journal of Clinical Investigation* (invited review) 108:785-791, 2001.
46. Febbraio M, AM Gotto, J Han, AC Nicholson, K Sharma, EA Podrez, HF Hoff, SL Hazen, **DP Hajjar**, and RL Silverstein: Regulation of CD36 by PPAR-gamma: Pro- or anti-atherogenic. In: *International Symposium on PPARs: From Basic Science to Clinical Applications*. JC Fruchart, AM Gotto, R. Paoletti, B Staels and A Catapano, eds. Klumer Academic Publishers, Dordrecht, Netherlands. pp.89-94, 2002.
47. **Hajjar DP** and AM Gotto, Jr: Targeting CD36: Modulating Inflammation and Atherogenesis. *Current Atherosclerosis Reports*, 5(3):155-156, 2003.
48. **Hajjar DP** and AM Gotto, Jr: Pleiotropic effects of arterial lipoprotein trafficking: understanding the cellular saboteurs. *Lipid Disorders Update*, 3(1):1-10, 2003.
49. Paoletti R, AM Gotto, **DP Hajjar**: Inflammation in Atherosclerosis and Implications for Therapy. *Circulation*, 109(l):1-7, 2004.
50. Nicholson AC and **DP Hajjar**: CD36, Oxidized LDL and PPAR γ : Pathological Interactions in Macrophages and Atherosclerosis. *Journal of General Pharmacology*, 41:139-146, 2004.
51. **Hajjar DP**, RS Deeb, and RK Upmacis: Complex Cross Talk Involving Nitric Oxide Metabolites: Who's Listening? *Current Atherosclerosis Reports*, 8:347-348, 2006.
52. Upmacis RK, RS Deeb and **DP Hajjar**: Oxidative Alterations of Cyclooxygenase During Atherogenesis. *Prostaglandins and Other Lipid Mediators*, 80:1-14, 2006.
53. Orth RN, M Foquet, JMM-Mirabal, H Craighead and **DP Hajjar**: Nanotechnology: Tools microbiologists can use to refine their research. In: *Handbook of Cosmetic Microbiology*, Ch. 16, pp. 227-247, 2006.

54. Deeb RS, RK Upmamis, BD Lamon and **DP Hajjar**: Maintaining equilibrium by selective targeting of cyclooxygenase pathways: promising offensives against vascular injury. *Hypertension*, 51:1-7, 2008.
55. Nuriel T, RS Deeb, **DP Hajjar** and SS Gross: Protein-3-nitrotyrosine in complex biological samples: quantification by HPLC-EC and emergence of proteomic approaches for unbiased identification of modification sites. In: *Methods in Enzymology*, Vol 441, Nitric Oxide, Part G. Cadenas and Packer, eds, 2008, pp.1-17.
56. Lamon BD and **DP Hajjar**: Inflammation at the molecular interface of atherogenesis: an anthropological journey. *American Journal of Pathology (invited review)* 173:1253-1264, 2008.
57. Deeb RS, BD Lamon and **DP Hajjar**: Silent Partner in Blood Vessel Homeostasis? Pervasive Role of Nitric Oxide in Vascular Disease. *Current Hypertension Reviews*, 5:273-282, 2009.
58. **Hajjar DP** and AM Gotto, Jr.: Biological Relevance of Inflammation and Oxidative Stress in the Pathogenesis of Arterial Diseases. *American Journal of Pathology (invited review)* 182: 1474-1481, 2013.
59. Deeb RS and **DP Hajjar**: Repair mechanisms in oxidant-driven chronic inflammatory disease. *American Journal of Pathology (invited review)*, in press, 2016
60. Hajjar DP: Cholesterol Metabolism: Role of Inflammation During Atherogenesis. *Journal of Enzymology and Metabolism (invited review)*, in press, 2016.

Books:

Hajjar DP and SM Schwartz: Role of Herpes Viruses in Atherosclerosis. Published by Harwood Academic Publishers GMBH, Reading, England, 220 pgs., 2000.

Educational and Science Policy Articles:

1. **Hajjar DP** and CK Smith: The ethical code of the scientist: Its role in the frontiers of science. *Science and Ethics* 1:13-15, 1978.
2. Bardes CL, JG Hayes, DJ Falcone, **DP Hajjar** and DR Alonso: Measuring Teaching: a relative value scale in teaching. *Teaching and Learning in Medicine* 10(1):40-43, 1998.
3. Sostman HD, **DP Hajjar**, and AM Gotto, Jr: Building a transcontinental affiliation: a new model for academic health centers. *Journal of Methodist DeBakey Heart Center* 1(4):11-13, 2005.

4. **Hajjar DP** and AM Gotto, Jr.: Launching of an American Medical School in the Middle East: Educational Challenges in a Multicultural Environment. *International Journal of Higher Education* 2(2): 67-75, 2013.
5. **Hajjar DP**, GW Moran, A Siddiqi, JE Richardson, LD Anadon, and V. Narayanmurti: Prospects for Policy Advances in Science and Technology in the Gulf Arab States: The Role for International Partnerships. *International Journal of Higher Education* 3(3): 45-57, 2014
6. **Hajjar DP**, JE Richardson and KD Coleman: Role of Diplomacy in Advancing Global Science, Technology, Engineering and Mathematics (STEM) Policies in the 21st Century. *Journal of Diplomacy and International Relations*, in press, 2016
7. **Hajjar DP**: U.S. Science Diplomacy as a Seed for the Advancement of Democracy in the Near East. *Journal of Diplomacy and International Relations*, in press, 2016.